Discover your next big idea for life sciences at PACK EXPO Las Vegas
Experience a breakthrough in life sciences packaging—explore solutions from 2,300 suppliers spanning all industries, all in one place this September

FDA: New Supply Chain Draft Guidance

With public meetings on security and data exchange, FDA releases guidance that helps companies “define the relationship” with trading partners. The agency is soliciting comments.

New FDA guidance includes sections that discuss repackagers, WDDs, 3PLs and dispensers, with subsections for partners such as brokers and common carriers.
New FDA guidance includes sections that discuss repackagers, WDDs, 3PLs and dispensers, with subsections for partners such as brokers and common carriers.

Supply chains are complicated, particularly when they involve brokers, wholesale distributors and repackagers. While the DSCSA establishes tracing requirements for various entities, there is confusion in the industry over which partners count as what entities under the law.

FDA’s new draft guidance document, “Identifying Trading Partners Under the Drug Supply Chain Security Act” may clear up some of that confusion once finalized by explaining requirements to the various entities and “help clarify for industry whetherthey are engaged in activities that require licensure and annual reporting, as well as other requirements related to being an authorized trading partner in the drug supply chain.”

The draft guidance includes sections that discuss the following as trading partners under the DSCSA: manufacturers, repackagers, wholesale drug distributors (WDDs), 3PLs and dispensers, with subsections for partners such as brokers and common carriers.

For example, FDA considers a broker as “a person or entity, who facilitates business transactions between two other trading partners, but does not take ownership of the product nor direct the sale or disposition of a product. A broker does not provide or coordinate warehousing and does not accept or transfer direct possession of the product and, therefore, is not considered a 3PL under DSCSA. Thus, FDA generally would not consider the 3PL licensure requirements under DSCSA to cover brokers.

Comments on the guidance will be accepted until October 23, 2017, and can be submitted electronically here.

Public meetings

FDA recently held a meeting in August on supply chain security in 2023 and enhanced drug distribution security needs, and has two additional meetings in the works:

FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?
Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report